Human mAbs are currently developed via one of three platforms: transgenic animals that express human immunoglobulins, bacteriophage display of human antigen-binding fragments, and yeast display of ...

Under the agreement, FairJourney will also acquire Charles Rivers’ Yeast Display method, allowing the Company to offer an expanded antibody discovery platform that can complement and enhance ...